Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc, a consumer health company focused on everyday health brands (e.g., Advil, Centrum, Panadol), covers the month of April 2026. The report, dated April 7, 2026, discloses aggregated information regarding transactions in the company's own shares under its share buyback programme announced on March 12, 2026.
Key Financial Metrics and Share Transactions
The filing details the purchase of 5,266,782 ordinary shares for cancellation across four trading sessions between March 30 and April 2, 2026. The transactions occurred on the London Stock Exchange, CBOE (UK)/BXE, and CBOE (UK)/CXE.
| Date | Total Shares Purchased | Price Range (pence) | Volume Weighted Avg Price (pence) |
|---|---|---|---|
| 30 March 2026 | 438,074 | 368.10 - 374.70 | 370.00 (approx) |
| 31 March 2026 | 1,300,000 | 373.60 - 379.10 | 375.97 (approx) |
| 1 April 2026 | 1,999,999 | 370.40 - 376.30 | 373.09 (approx) |
| 2 April 2026 | 1,528,708 | 369.50 - 374.10 | 371.63 (approx) |
| Total | 5,266,781 | 368.10 - 379.10 | N/A |
Note: The filing text lists a total of 5,266,782 shares purchased, while the sum of the daily breakdowns provided in the text totals 5,266,781. The filing states the total figure as 5,266,782.
Following these transactions, the company's registered share capital stands at 8,927,564,553 ordinary shares of £0.01 each. Of these, 12,493,360 are held as treasury shares, leaving 8,915,071,193 ordinary shares with voting rights.
Material Changes
The primary material change reported is the reduction in the number of outstanding shares due to the buyback and cancellation programme. The filing does not provide comparative financial data (revenue, profit, cash flow) for the period or versus prior periods, as this is a transaction-specific disclosure rather than a financial results report.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial performance, or discussion of risks and contingencies beyond the standard disclaimer that the announcement does not constitute an offer of securities. The company directs investors to its website for further information.
Key Facts for Investor Verification
- Verify the total number of shares purchased (5,266,782) against the sum of daily trades reported in the breakdown.
- Confirm the updated number of voting shares (8,915,071,193) for disclosure threshold calculations under FCA rules.
- Review the full trade breakdown available via the provided RNS link for granular pricing data.
- Note that this filing does not contain quarterly or annual financial performance metrics.